Global Sirolimus Market Regional Insights
North America is expected to dominate the global sirolimus market due to an increasing number of product approvals for preventing organ transplant rejection. For instance, one of the major leading company Pfizer Inc. has carried out various clinical trial studies on sirolimus 1mg/2mg dose for different treatments such as graft rejection, kidney transplant, renal allograft recipients, and renal transplants which has successfully completed phase IV in 2013. Furthermore, growing demand for kidney transplants is expected to propel growth of the global sirolimus market growth over the forecast period. According to the National Kidney Foundation, 2014 in U.S. data, every month approximately 3,000 patients were added to the kidney transplant waiting list, and an estimated 13 people died each day while waiting for a life-saving kidney transplant.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients